• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

    4/24/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email

    SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025.

    Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.

    About CeriBell, Inc.

    Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

    Investor Contact

    Brian Johnston or Laine Morgan

    Gilmartin Group

    [email protected]

    Media Contact

    Corrie Rose

    [email protected]



    Primary Logo

    Get the next $CBLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innovations in healthcare, so far ambient scribes have emerged as the breakout use case. As the range of AI uses for the healthcare sector continues to grow, experts are analyzing the potential ROI on their implementation, and how much they'll benefit early adopters. Healthcare leaders are already seeing improvements, such as slashed clinician workloads from voice AI, and the adoption of AI agents to increase efficiency and smarter care delivery. For investors looking for remaining early-mover advantages, ther

      6/20/25 9:11:00 AM ET
      $CBLL
      $GEHC
      $MDAI
      $PLTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical Electronics
      Medical/Dental Instruments
    • Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

      SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.  Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m. CST A live and archived webcast of the presentation will be available in the "Inv

      5/20/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robertson Rebecca B sold $330,961 worth of shares (18,633 units at $17.76), decreasing direct ownership by 65% to 10,042 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      6/20/25 12:31:36 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Robertson Rebecca B was granted 8,828 shares, exercised 20,000 shares at a strike of $3.61 and sold $342,800 worth of shares (20,000 units at $17.14), increasing direct ownership by 44% to 28,675 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      6/17/25 7:52:14 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Tammenoms Bakker Juliet was granted 8,828 shares, increasing direct ownership by 133% to 15,446 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      6/17/25 7:50:35 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on CeriBell with a new price target

      Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      4/4/25 8:27:23 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BofA Securities initiated coverage on CeriBell with a new price target

      BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      11/5/24 7:25:17 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Canaccord Genuity initiated coverage on CeriBell with a new price target

      Canaccord Genuity initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

      11/5/24 6:16:50 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/17/24 4:14:38 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/16/24 4:18:06 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    SEC Filings

    See more
    • CeriBell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Ceribell, Inc. (0001861107) (Filer)

      6/20/25 12:45:39 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by CeriBell Inc.

      144 - Ceribell, Inc. (0001861107) (Subject)

      6/18/25 1:23:53 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by CeriBell Inc.

      144 - Ceribell, Inc. (0001861107) (Subject)

      6/17/25 10:19:07 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care